Company intelligence / Profile preview

Sinobioway Group Co., Ltd.

Ownership: Private
Employees: ~1000
Development stage: Clinical

Overview

The company has successfully developed and commercialized multiple products including the world's first drug treatment for traumatic nerve injury (nerve growth factor), inactivated SARS virus vaccine, and China's first human-use influenza vaccine. Their flagship product NOBEX is used for treating nerve system syndromes[2][3].

Therapeutic areas: NeurologyInfectious Diseases
Modalities: VaccinesBiopharmaceuticalsPeptide drugsMonoclonal antibody drugs
Industry: Pharma

Drug pipeline

5 assets

Sino19

4 more assets in the full pipeline.

Request access →

Partnerships

BioAtla (California-based biotech firm)

Beyond the preview

Go deeper on Sinobioway Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinobioway Group Co., Ltd..

Explore the full profile